# PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

> **NCT03774732** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 327 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non-Small Cell Carcinoma of Lung, TNM Stage 4

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Pembrolizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03774732
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-24
- **Primary completion:** 2026-12-22
- **Final completion:** 2026-12-22
- **Target enrollment:** 327 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03774732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03774732, "PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03774732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*